. . . . . "The continued global demand for Zoladex, particularly in Japan and emerging markets including China and Russia, has resulted in the decision to invest in replacing some of the existing facilities where the medicine is currently produced at the Macclesfield site. ???Having considered a number of options globally, we believe it is the right choice to build the new facility in Macclesfield, which has" . .